EGFR-directed therapies to treat non-small-cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 18, Issue 8, 2009, Pages 1133-1145

  Ho, Cheryl ^a   Laskin, Janessa ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

EGFR; Monoclonal antibody; Predictive marker; Tyrosine kinase inhibitor

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIB 2992; BIBW 2992; BIOLOGICAL MARKER; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; NERATINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TOVOK; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 647;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EGFR GENE; FATIGUE; GENE; GENE MUTATION; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; RASH; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN DEFECT; SOLID TUMOR; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 68049140903     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903066772     Document Type: Review

References (62)

1. National Cancer Institute. Available from: http://www.cancer.gov/ cancertopics/types/lung
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
3. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
4. Laskin JJ, Sandler AB. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat Rev 2004;30:1-17
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
7. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62
8. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
9. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73
10. Giaccone G, Iacona RB, Fandi A, et al. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 2009;135:467-76
11. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
12. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55
13. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63
14. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-8
15. Buckingham LE, Coon JS, Morrison LE, et al. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol 2007;2:414-22
16. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 2005;366:1527-37
17. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7
18. Schittenhelm MM, Kollmannsberger C, Oechsle K, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009;8:481-9
19. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-52
23. NCT00349219. TORCH: a study of tarceva or chemotherapy for the treatment of advanced non small cell lung cancer
24. NCT00556712. SATURN: a phase III trial of erlotinib following chemotherapy as 1st line treatment for non-small cell lung cancer
25. NCT00300586. Available from: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid =473226&version= HealthProfessional&protocolsearchid=5588535
26. NCT00257608. A study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (ATLAS)
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
28. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
29. NCT00556322. TITAN tarceva in treatment of advanced NSCLC, erlotinib versus pemetrexed or docetaxel second-line
30. NCT00130728. BeTa A study to evaluate the efficacy of bevacizumab in combination with tarceva for advanced non-small cell lung cancer
31. NCT00373425. RADIANT: a study of tarceva after surgery with or without adjuvant chemotherapy in non-small cell lung cancer (NSCLC) patients who have epidermal growth factor receptor (EGFR) - positive tumors
32. NCT00153803. Erlotinib or placebo following chemoradiotherapy (Chemo/RT) in stage III non-small cell lung cancer (NSCLC)
33. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003;21:2237-46
34. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005;23:2946-54
35. Natale RB. Effects of ZD1839 (iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Semin Oncol 2004;31:23-30
36. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84
37. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94
38. Mok T, Wu Y, Thongprasert S, et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008;19:LBA2
39. Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of west japan thoracic oncology group trial (WJTOG). ASCO Meeting Abstracts 2008;26:LBA8012
40. NCT00091156. Phase III randomized study of adjuvant gefitinib after previous first-line palliative induction chemotherapy in patients with stage IIIB or IV non-small cell lung cancer
41. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52
42. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18
43. Lee D, Kim S, Park K, et al. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. ASCO Meeting Abstracts 2008;26:8025
44. NCT00049543. BR19 gefitinib in treating patients with non-small cell lung cancer that has been surgically removed
45. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6
46. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the hoosier oncology group and U.S. oncology. J Clin Oncol 2008;26:5755-60
47. Spicer J, Calvert H, Vidal L, et al. Activity of BIBI 2992 an oral irreversible dual EGFR/HER2 inhibitor in non small cell lung cancer with mutated EGFR. JTO 2007;2:S410-D7-02
48. NCT00656136: BIBW 2992 (TOVOK) and BSC versus placebo and BSC in non-small cell lung cancer patients failing erlotinib or gefitinib (LUX-LUNG 1)
49. Janne PA, von Pawel J, Cohen RB, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007;25:3936-44
50. Chiappori AA, Ellis PM, Hamm JT, et al. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;1:1010-9
51. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-70
52. Wong KK, Fracasso PM, Bukowski RM, et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. ASCO Meeting Abstracts 2006;24:3018
53. NCT00266877. Study evaluating the safety of HKI-272 in subjects with advanced non-small cell lung cancer
54. Gendreau SB, Ventura R, Keast P, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007;13:3713-23
55. Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): B3-03. J Thorac Oncol 2007;2:S340
56. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
57. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer [corrected]. J Clin Oncol 2007;25:5777-84
58. Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): Results of OPN-017. J Thorac Oncol 2008;3:1286-92
59. Socinski MA, Saleh MN, Trent DF, et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2009;20:1068-73
60. Kollmannsberger C, Schittenhelm M, Honecker F, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17:1007-13
61. Bebb DG, Brade AM, Smith C, et al. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. ASCO Meeting Abstracts 2008;26:3037
62. Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2004;22:7083